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Abstract  
Background: A significant proportion of severe familial forms of obesity remain genetically 
elusive. Taking advantage of our unique cohort of multi-generation obese families, we aimed 
to assess the contribution of rare mutations in 29 common obesity-associated genes to familial 
obesity, and to evaluate in these families the putative presence of nine known monogenic 
forms of obesity.  
Methods: Through next-generation sequencing, we sequenced the coding regions of 34 genes 
involved in polygenic and/or monogenic forms of obesity in 201 participants (75 normal 
weight individuals, 54 overweight individuals and 72 individuals with obesity class I, II or 
III), from 13 French families. In vitro functional analyses were performed to investigate the 
mutation PCSK1-p.Arg80* which was identified in a family.   
Results: A novel heterozygous nonsense variant in PCSK1 (p.Arg80*), encoding a propeptide 
truncated to less than two exons (out of 14), was found to co-segregate with obesity in a three-
generation family. We demonstrated that this mutation inhibits PCSK1 enzyme activity and 
that this inhibition most likely does not involve a strong physical interaction. Furthermore, 
both mutations PCSK1-p.Asn180Ser and POMC-p.Phe144Leu, which had previously been 
reported to be associated with severe obesity, were also identified in this study, but did not co-
segregate with obesity. Finally, we did not identify any rare mutations co-segregating with 
obesity in common obesity susceptibility genes, except for CADM2 and QPCTL, where we 
found two novel variants (p.Arg81His and p.Leu98Pro, respectively) in three obese 
individuals.   
Conclusions: We showed for the first time that a nonsense mutation in PCSK1 was likely to 
cause dominantly inherited human obesity, due to the inhibiting properties of the propeptide 
fragment encoded by the null allele. Furthermore, the present family sequencing design 
challenged the contribution of previously reported mutations to monogenic or at least severe 
obesity.  
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Introduction 
Obesity has become one of the most important non-communicable pandemic diseases
1
. Many 
risk factors can explain this situation such as environmental causes but also strong genetic 
predispositions
1, 2
. Indeed, the heritability of body mass index (BMI) has been estimated to 
range between 40% and 70%
1, 2
. To date, BMI variation (or risk of common obesity) has 
been shown to be associated with more than 60 frequent single nucleotide polymorphisms 
(SNPs), which have mostly been identified by genome-wide association studies (GWAS)
3
. 
However, the overall contribution of these SNPs to BMI variation (or obesity risk) explains 
less than 15% of its heritability
3
. Recent studies have shown that rare coding mutations with 
strong effect and located in loci associated with type 2 diabetes or age-related macular 
degeneration (primarily identified by GWAS) may contribute to the missing heritability of 
these common diseases
4-7
. However, to our knowledge, such analyses have never been 
investigated in obesity so far. 
On the other hand, rare coding mutations (or deletions) in nine genes (BDNF
8, 9
, LEP
10, 11
, 
LEPR
12
, MC4R
13-15
, NTRK2
16
, PCSK1
17
, POMC
18
, SH2B1
19
, SIM1
20, 21
) have been shown to 
cause severe early-onset obesity (mostly monogenic forms of obesity). Most of the proteins 
encoded by these genes play a key role in the leptin-melanocortin signaling pathway, which 
regulates appetite
1, 2
. Interestingly, frequent SNPs within (or close to) BDNF, MC4R, PCSK1, 
POMC and SH2B1 have also been shown to contribute to common obesity risk
1-3, 22
. In 
addition, we can hypothesize that mutations in those genes may also co-segregate with obesity 
in families. 
In the present study, we took advantage of our unique cohort of multi-generation obese 
families. We assessed the contribution of rare mutations in common obesity-associated genes 
to familial obesity in 13 large French pedigrees. Furthermore, we evaluated the putative 
presence of known monogenic forms of obesity in these families. For this purpose, we 
©    2014 Macmillan Publishers Limited. All rights reserved.
4 
 
sequenced 34 genes involved in polygenic and/or monogenic forms of obesity in 13 large 
French families, via next-generation sequencing (NGS).  
©    2014 Macmillan Publishers Limited. All rights reserved.
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Materials and methods 
Patient selection 
The study protocol was approved by all local ethics committees, and informed consent was 
obtained from each subject before participation in the study, in accordance with the 
Declaration of Helsinki principles. For children younger than 18 years, oral consent was 
obtained, and parents provided written informed consent. 
The obese French adults and children were recruited either by the CNRS UMR8199 (Lille, 
France), by the Department of Nutrition of Hotel-Dieu Hospital (Paris, France) or by the 
‘Centre d'Etude du Polymorphisme Humain’ (CEPH, Saint-Louis hospital, Paris, France). 
We selected 13 large French families including a total of 227 individuals with available 
clinical data, but 201 DNA samples satisfied quality and quantity criteria for NGS (Table 1). 
Large pedigrees including a proband whose the monogenic cause of obesity had been 
elucidated in previous studies were excluded from the selection
15, 20, 23, 24
.     
Obesity classes were described as following: normal weight, BMI < 25; overweight, 25 ≤ 
BMI < 30; obesity class I, 30 ≤ BMI < 35; obesity class II, 35 ≤ BMI < 40; obesity class III, 
40 ≤ BMI.      
 
Selection of the targeted genes 
We selected a total of 34 genes: 29 genes that were found to be associated with BMI variation 
or risk of common obesity
1, 3
, and nine genes that were found to be mutated in monogenic 
forms of obesity
2, 18-20
 (Table 2).   
 
Target enrichment and next-generation sequencing 
Sequence capture of targeted regions (including exonic regions with a flanking 50 base pairs 
[bp] into each intron) was performed according to the manufacturer's protocol using 
SureSelect custom design reagent (Agilent Technologies, Santa Clara, CA, USA).  
©    2014 Macmillan Publishers Limited. All rights reserved.
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Briefly, 3µg of DNA was shorn by sonication (Bioruptor NGS, Diagenode, Liège, Belgium) 
and purified using Agencourt AMPure XP beads (Beckman Coulter, Fullerton, CA, USA). 
The fragment ends were repaired and adaptors were ligated to the fragments. The resulting 
DNA library was amplified by PCR and captured by hybridization to the biotinylated RNA 
library baits. Bound genomic DNA was purified with streptavidin coated magnetic Dynabeads 
(Invitrogen, Carlsbad, CA, USA) and re-amplified. 
After capture, the enriched DNA samples were quantified using qPCR. Then, we performed 
100bp paired-end (PE) read sequencing using the Illumina Genome Analyzer IIx (Illumina, 
San Diego, CA, USA), according to the manufacturer’s recommendations. 
 
Data analysis 
For each run, demultiplexing of sequence data was performed with CASAVA (version 1.8.2, 
Illumina) to generate FASTQ files for each sample. Subsequently, sequence reads were 
mapped to the Human genome (hg19/GRC37) using the Burrows-Wheeler Aligner (BWA, 
version 0.6.1) to generate a BAM file. Variant calling was performed using SAMtools 
(version 0.1.18). The output VCF files were filtered using quality threshold of read depth ≥ 8× 
and were annotated by extracting several features from Ensembl database: gene symbol and 
description, amino acid change, presence in dbSNP135, presence in 1000 Genomes and minor 
allele frequency in CEU population. Predictions of functional effects were also analyzed using 
dbNSFP
25
 to integrate prediction scores from PolyPhen2
26
, SIFT
27
, MutationTaster
28
 and 
LRT
29
. 
 
Sanger Sequencing 
When putative causal variants were found, we confirmed their presence by Sanger sequencing 
via the 3730×l DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Primers were 
designed using VisualOMP. Primer sequences and PCR conditions can be provided upon 
©    2014 Macmillan Publishers Limited. All rights reserved.
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request. Sequencing reads were assembled and analyzed with Variant Reporter software 
(Applied Biosystems). 
 
Cloning of constructs 
Site directed mutagenesis was performed using the QuikChange II kit (Stratagene) using the 
FLAG-tagged PCSK1 construct described previously as template
17
. The following mutations 
were introduced: p.Arg80*, p.Arg110*, p.Leu58Met, p.Leu58Met-p.Arg80*. Mutations were 
confirmed by Sanger sequencing.   
 
Cell culture 
HEK293T cells were plated in 3.4cm² or 10cm² dishes and transfected the next day with 
empty vector (pcDNA3; Invitrogen), human wild type PCSK1, PCSK1-p.Arg80* or PCSK1-
pArg110* using Xtreme gene 9 transfection reagent (Roche Applied Science, Basel, 
Switzerland) according to the manufacturers protocol. Confluent wells were incubated with 
DMEM/F12 (Life Technologies) serum free medium overnight and conditioned medium was 
subsequently used for in vitro PCSK1 (or PC1/3) activity assay. Alternatively, cells were used 
for metabolic labeling. 
 
Activity assay 
PC1/3 enzymatic activity was assessed as previously described
30
. Briefly, 25µl conditioned 
medium from cells expressing different constructs was incubated in a total reaction volume of 
50µl containing 0.2mM synthetic substrate Pyr-Glu-Arg-Thr-Lys-Arg-amino methylcoumarin 
(Bachem, Bubendorf, Switzerland), 5mM CaCl2,  0.1M Na-acetate (pH 5.5), 0.1% Triton X-
100, 10 μM E-64, 1 μM leupeptin, 10 μM pepstatin, and 100 μM tosyl phenylalanyl 
chloromethyl ketone (Sigma-Aldrich, St. Louis, MO). Each sample contained conditioned 
©    2014 Macmillan Publishers Limited. All rights reserved.
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medium from cells transfected with wild type PC1/3 combined with medium from cells 
transfected with different constructs as indicated in a ratio of 4:1.  
 
Metabolic labeling 
HEK293T cells were metabolically labeled as previously described
30
. Briefly, 10cm² dishes 
with HEK293T cells were transfected with empty vector, wild type PCSK1, PCSK1-
p.Leu58Met and/or PCSK1-p.Leu58Met-p.Arg80*. PCSK1 and PCSK1-p.Leu58Met contain a 
FLAG-tag between the propeptide and the catalytic domain. Transfected cells were 
metabolically labeled for 2h and chased for 1h. Co-immunoprecipitation experiments were 
performed with FlagM1 antibody (Sigma Aldrich, St. Louis, MO). FlagM1 only recognizes 
epitopes at a free amino terminus and will therefore only recognize PC1/3 cleaved 
carboxyterminal of RSKR-110.  
 
Immunoblotting 
Protein samples were prepared from lysate and conditioned medium from HEK293T cells 
expressing either wild type PCSK1 with or without PCSK1-p.Arg80* or PCSK1-pArg110*. 
Wild type PC1/3 was detected with FlagM2 antibody (Sigma-Aldrich, St. Louis, MO), as 
previously described
17
.  
  
©    2014 Macmillan Publishers Limited. All rights reserved.
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Results 
Using NGS, we sequenced 34 genes involved in monogenic and/or polygenic obesity (Table 
2) in 201 participants (including 75 normal weight individuals, 54 overweight individuals, 36 
individuals with obesity class I, 18 individuals with obesity class II and 18 individuals with 
obesity class III), from 13 large French families with at least three generations (Table 1). 
Except for FAIM1, POMC, QPCTL and SH2B1 genes, the median depth of coverage per gene 
was above 100× (Table 2). 
We identified a total of 44 rare variants of interest (i.e. non-synonymous variants, essential 
splice-site variants, indels or nonsense variants with a minor allele frequency [MAF] below 
1%), of which 22 were novel (Table 3). Among them, three non-synonymous variants were 
only carried by obese individuals (in a heterozygous state): p.Arg80* in PCSK1 (three carriers 
in Family #11; Table 3), p.Arg81His in CADM2 (two carriers in Family #9; Table 3) and 
p.Leu98Pro in QPCTL (one carrier in Family #4; Table 3). 
The PCSK1 p.Arg80* nonsense mutation was carried by patient #I2 with obesity class III, and 
by patients #II1 and #III1 who both presented with obesity class I (Figure 1). No normal 
weight subjects of Family #11 carried this mutation (Figure 1). However, the obese child 
#III3, sister of patient #III1, did not carry the mutation, thus she was likely to be a phenocopy 
(Figure 1). Of note, mutated patient #I2 with obesity class III also presented with type 2 
diabetes (fasting plasma glucose [FPG] = 11 mmol/L) and her mutated son #II1 was pre-
diabetic (FPG = 6.5 mmol/L). Episodes of diarrhea were not reported by the carriers, when we 
specifically asked them if they presented with malabsorption during their infancy. As the 
p.Arg80* nonsense mutation occurred at the beginning of PCSK1 (encoding proprotein 
convertase PC1/3 which includes a total of 753 amino acids), the lack of function of the 
protein was very likely. In order to investigate whether the mutant propeptide fragment 
(encoded by PCSK1-p.Arg80*; Figure 2a) inhibits the wild type (WT) PC1/3 enzyme, an 
activity assay was performed using a fluorogenic substrate. The incubation of conditioned 
©    2014 Macmillan Publishers Limited. All rights reserved.
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medium containing both mutant propeptide fragment and WT PC1/3 decreased the activity of 
the latter by 20.0% (P=0.02, Student T test; Figure 2b). Of note, the inhibition was similar to 
inhibition of WT PC1/3 by the full-length propeptide of PC1/3 encoded by PCSK1-p.Arg110* 
(25.0%, P=0.006; Figures 2a and 2b), which has previously been shown to inhibit PC1/3
31
. 
Subsequently, we investigated the physical interaction between the mutant propeptide 
fragment (PC1/3-p.Arg80*) and WT PC1/3. For this purpose, we considered that PC1/3 
propeptide (PC1/3-p.Arg110*) does not contain any methionines but that a methionine can be 
introduced at position 58 (p.Leu58Met) without interfering with normal protein maturation 
(Figure 2a)
30
. The full-length propeptide and the aminoterminal fragment of the cleaved 
propreptide co-immunoprecipitated with mature PC1/3-p.Leu58Met-p.Arg110, as previously 
shown
30
, while we did not observed any co-immunoprecipitation between mutant PC1/3-
p.Leu58Met-p.Arg80* and WT PC1/3 (Figure 2c). We subsequently investigated the 
maturation and secretion of WT PC1/3 in the presence or absence of PC1/3-p.Arg80* and the 
full-length propeptide of PC1/3 (PC1/3-p.Arg110*). Interestingly, we observed an increase in 
WT PC1/3 protein level in the presence of either complete or partial propeptide (PC1/3-
p.Arg110* or PC1/3-p.Arg80*, respectively), indicating that the propeptide may retain WT 
PC1/3 in the endoplasmic reticulum or slows down intracellular transport (Figure 2d). 
Therefore, we demonstrated that the p.Arg80* nonsense mutation inhibits WT PC1/3 activity 
and that this inhibition most likely does not involve a strong physical interaction. 
The CADM2 p.Arg81His missense mutation was carried by an obese patient (BMI=31.6 at 69 
years old) and her son presenting with obesity class II (BMI=37.4 at 43 years old; 
Supplementary Figure 1). This novel mutation was predicted to be probably deleterious 
according to dbNSFP (Table 3). Unfortunately, it was impossible to study a possible 
segregation of the mutation with obesity in Family #9 as the mother was outside the family 
and her son did not have any children (Supplementary Figure 1).  
©    2014 Macmillan Publishers Limited. All rights reserved.
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The QPCTL p.Leu98Pro missense mutation was carried by an adult presenting with obesity 
class III (BMI=52.0 at 60 years old). Her six brothers and sisters, with obesity, overweight or 
normal weight, did not carry this novel mutation, as well as her normal weight son 
(Supplementary Figure 2). Therefore, it was difficult to draw clear conclusions about this 
mutation, even if it was predicted to be deleterious according to dbNSFP (Table 3).   
Interestingly, in the present study, we identified previously reported rare missense variants in 
PCSK1 (p.Asn180Ser; Table 3)
23
, MC4R (p.Ile251Leu; Table 3)
14
 and POMC (p.Phe144Leu 
and p.Glu214Gly; Table 3)
32, 33
, which were all present in the Human Gene Mutation 
Database (HGMD).  
We previously reported the PCSK1 p.Asn180Ser variant in two unrelated obese patients and 
we demonstrated its mild deleterious effect on the activity of the encoded protein, the 
proprotein convertase 1/3
23
. However, in the present study, this mutation was found in a 
normal weight adult (with a BMI of 20.2 at 42 years old) and his normal weight son 
(BMI=21.5 at 18 years old). The PCSK1 p.Asn180Ser mutation was not identified in obese 
members of the same family, which lessened a marked contribution of this mutation to obesity 
in this family.  
The rare MC4R p.Ile251Leu variant (rs52820871; MAF [European population] = 0.4%) was 
identified in an adult presenting with obesity class II (BMI=37.5 at 55 years old) and her non-
obese son (BMI=25.7 at 32 years old) as well as her two normal weight daughters (BMI=24.7 
at 31 years old and BMI=18.5 at 21 years old) in Family #6. These results are not in 
contradiction with our previous study which demonstrated a protective effect of the MC4R 
p.Ile251Leu variant in large cohorts
34
. The obesity of the mother was probably due to another 
genetic etiology.    
The POMC p.Phe144Leu variant (rs201408477; MAF [European population] = 0.1%) was 
previously reported in one obese child and his obese father, and was shown to be strongly 
deleterious as this mutation dramatically altered POMC binding to MC4R
32
. In the present 
©    2014 Macmillan Publishers Limited. All rights reserved.
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study, the POMC p.Phe144Leu mutation was identified in three non-obese sisters (BMI=23.7, 
23.9 and 29.0 at 24, 25 and 25 years old, respectively) from Family #1, lessening a significant 
contribution of this mutation to obesity in this family. 
The POMC p.Glu214Gly variant (rs80326661; MAF [European population] = 0.3%) was 
previously reported in a 16.5 years old female obese adolescent who also carried an insertion 
and a nonsense mutation in the same gene (in a heterozygous state)
33
. In the present study, the 
heterozygous mutation was carried by a normal weight adult (BMI=24.9 at 76 years old), and 
was transmitted to her obese daughter (BMI=43.0 at 48 years old) and to her normal weight 
granddaughter (BMI Z-score=0.27 at 14 years old) in Family #7, lessening a strong 
contribution of this mutation to obesity in this family. 
 
  
©    2014 Macmillan Publishers Limited. All rights reserved.
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Discussion 
In the present study, by assessing the contribution of rare mutations to common or monogenic 
obesity-associated genes in 201 individuals, from 13 large French pedigrees with familial 
obesity, we identified a novel nonsense mutation (c.238C>T / p.Arg80*) in PCSK1 (in a 
heterozygous state) which is likely to cause obesity in a three-generation family.   
PCSK1 encodes the proprotein convertase subtilisin/kexin type 1 (also known as proprotein 
convertase PC1/3) which is considered the major processing enzyme of prohormones 
(including proinsulin, proopiomelanocortin, proglucagon, prorenin, progastrin, 
progonadotrophin releasing hormone…) involved in a broad of endocrine, enteroendocrine 
and neuronal pathways
23, 35
. Genetic association studies in large cohorts showed that common 
single nucleotide polymorphisms (SNPs) in PCSK1 contributed to increased risk of obesity
22
 
and to variation of both fasting proinsulin levels and fasting plasma glucose levels
36
. All these 
associations were highly significant but harbored a weak effect, which was typical for 
common SNPs. In contrast, rare congenital deficiency of PCSK1 has been reported so far in 
less than 20 unrelated probands (carrying homozygous or compound heterozygous mutations) 
who presented with malabsorptive diarrhea, failure to thrive during early infancy associated 
with high mortality rate, severe early onset obesity, polyphagia, central diabetes insipidus, 
hypogonadism, hyperproinsulinemia and other endocrine dysfunctions
17, 30, 37-39
. Notably, it 
appeared that when congenital carriers of PCSK1 mutations experienced severe failure to 
thrive during early infancy because of persistent malabsorption, they only presented with 
moderate obesity during late childhood and adolescence
39
. It could be explained by the 
homozygosity of highly deleterious variants (including nonsense or frameshift mutations) 
carried by these patients
39
. Martín and colleagues hypothesized that when the recessive 
mutations are milder, the carriers present with a more profound obesity
39
. Furthermore, we 
previously reported a significant enrichment of rare heterozygous variants in PCSK1 causing 
partial PCSK1 deficiency, in unrelated obese individuals
23
. However, the vertical transmission 
©    2014 Macmillan Publishers Limited. All rights reserved.
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of these mild loss-of-function variants was not investigated in families and they were not fully 
penetrant (with an odds ratio of ~8)
23
. In the present study, we showed that a nonsense 
heterozygous mutation (p.Arg80*) at the beginning of PCSK1 co-segregated with obesity in 
three generations of a French family, following a dominant mode of inheritance. Of note, the 
propeptide of PC1/3 (PC1/3-p.Arg110*; Figure 2a) functions as an intramolecular chaperone, 
essential for folding and transport through the secretory pathway. The propeptide is cleaved at 
position 110 in the endoplasmic reticulum by an intramolecular process
40
. However, in the 
p.Arg80* mutation carriers, the propeptide remains associated with PC1/3 till the late Golgi 
compartments where a second cleavage at position 80 occurs and the two fragments dissociate 
from PC1/3
41
. The effect of the propeptide in trans has been shown to act as a slow tight-
binding inhibitor of the native enzyme
31
. The main inhibitory potency of the propeptide has 
been attributed to the carboxy-terminal region of the prodomain
42, 43
. Here, we demonstrated 
that the amino-terminal propeptide, only containing the sequence up till the cleavage site at 
position 80, was able to inhibit WT PC1/3 activity and that this inhibition most likely does not 
involve a strong physical interaction. The observation that both amino-terminal propeptide 
(PC1/3-p.Arg80*) and the full-length propeptide (PC1/3-p.Arg110*) increase the amount of 
intracellular WT PC1/3 is a novel finding which suggests that in addition to the inhibition, the 
propeptide has additional effects on PC1/3 trafficking and stability. Therefore, the mutation 
found in the family does not only inactivate one PCSK1 allele, but its gene product also 
interferes with the functioning of the gene product of the unaffected allele. This is a likely 
explanation for the dominant inheritance of the obesity phenotype. However, the inhibition of 
PC1/3 is only partial which would explain why no multihormonal disorder is observed in 
these patients, in contrast to the phenotype of PCSK1 null patients
39
. To our knowledge, it is 
the first demonstration that partial haploinsufficiency of PCSK1 can cause a dominant form of 
familial obesity.      
©    2014 Macmillan Publishers Limited. All rights reserved.
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In summary, PCSK1 can harbor different genetic events with various frequencies, which are 
associated with a wide range of phenotypes: 1/ rare null mutations causing congenital PCSK1 
deficiency, which lead to diarrhea, failure to thrive, early onset obesity and a plethora of other 
severe clinical features
17, 30, 37-39
; 2/ a rare nonsense loss-of-function mutation at the 
heterozygous state, causing a dominant form of mendelian familial obesity associated with 
glucose intolerance; 3/ partial loss-of-function heterozygous mutations conferring high risk 
for common obesity
23
; and finally 4/ frequent SNPs associated with a mild increase in risk of 
common obesity, and modest variations of both fasting proinsulin levels and fasting plasma 
glucose levels
22, 36
.  
With regard to the other genes involved in monogenic obesity, we did not identify any 
putatively causal mutations leading to obesity in the 12 remaining families. Notably, our 
family sequencing design lessened the marked contribution of previously reported mutations 
in PCSK1 (p.Asn180Ser)
23
 or POMC (p.Phe144Leu)
32
 to monogenic or at least severe 
obesity. It shows the power of family study to evaluate the true contribution of rare mutations, 
even in excellent candidate genes, to disease risk. 
Finally, we did not find any rare mutations co-segregating with obesity in common obesity 
susceptibility genes, except for two GWAS identified genes (CADM2 and QPCTL) which 
may deserve further genetic investigations. No rare coding mutations in these two genes have 
been listed in the HGMD database. CADM2 encodes the cell adhesion molecule 2, which 
belongs to the immunoglobulin superfamily and plays a key role in the cytoskeleton, while 
QPCTL encodes the glutaminyl-peptide cyclotransferase-like. Expression of both of these 
genes was shown to be modified in cancers
44, 45
.    
In conclusion, we identified a novel nonsense mutation in PCSK1 in the heterozygous state 
which caused obesity in three generations from a French family. We did not find any other 
rare mutations (among the list of sequenced genes) co-segregating with obesity in the 12 
remaining families, which may be surprising. We could imagine two possibilities: 1/ the 
©    2014 Macmillan Publishers Limited. All rights reserved.
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causal mutations are elsewhere in the genome and thus we should perform whole-exome 
sequencing or whole-genome sequencing to find them; 2/ the obesity in these families is 
polygenic and depends on multiple genetic and epigenetic variants in interaction (or not) with 
the nurture.  
 
 
Acknowledgements 
We are sincerely indebted to all participants in the genetic study. We thank Marianne 
Deweirder and Frédéric Allegaert for their technical assistance and their management of DNA 
samples. We are grateful to Philippe Gallina for his invaluable help for the recruitment of 
families.  
This study was supported by: the Genoscope, the EU-founded EurOCHIP FP7 consortium 
and ‘Centre National de la Recherche Scientifique’ (CNRS), ‘FWO-Vlaanderen’ and ‘IWT’. 
 
 
Conflict of Interest 
The authors declare no competing financial interests. 
 
 
Supplementary information 
Supplementary information is available at International Journal of Obesity’s website.  
©    2014 Macmillan Publishers Limited. All rights reserved.
17 
 
References 
1. El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized 
obesity therapy. Nature reviews. Endocrinology 2013; 9(7): 402-413. 
 
2. Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. 
The Journal of clinical investigation 2011; 121(6): 2080-2086. 
 
3. Berndt SI, Gustafsson S, Mägi R, Ganna A, Wheeler E, Feitosa MF et al. Genome-
wide meta-analysis identifies 11 new loci for anthropometric traits and provides 
insights into genetic architecture. Nature genetics 2013; 45(5): 501-512. 
 
4. Bonnefond A, Clément N, Fawcett K, Yengo L, Vaillant E, Guillaume J-L et al. Rare 
MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 
diabetes. Nature genetics 2012; 44(3): 297-301. 
 
5. Helgason H, Sulem P, Duvvari MR, Luo H, Thorleifsson G, Stefansson H et al. A rare 
nonsynonymous sequence variant in C3 is associated with high risk of age-related 
macular degeneration. Nature genetics 2013. 
 
6. Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S et al. Rare variants 
in CFI, C3 and C9 are associated with high risk of advanced age-related macular 
degeneration. Nature genetics 2013. 
 
7. Zhan X, Larson DE, Wang C, Koboldt DC, Sergeev YV, Fulton RS et al. 
Identification of a rare coding variant in complement 3 associated with age-related 
macular degeneration. Nature genetics 2013. 
 
8. Gray J, Yeo GSH, Cox JJ, Morton J, Adlam A-LR, Keogh JM et al. Hyperphagia, 
severe obesity, impaired cognitive function, and hyperactivity associated with 
functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. 
Diabetes 2006; 55(12): 3366-3371. 
 
9. Han JC, Liu Q-R, Jones M, Levinn RL, Menzie CM, Jefferson-George KS et al. 
Brain-derived neurotrophic factor and obesity in the WAGR syndrome. The New 
England journal of medicine 2008; 359(9): 918-927. 
 
10. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. 
Congenital leptin deficiency is associated with severe early-onset obesity in humans. 
Nature 1997; 387(6636): 903-908. 
 
11. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation 
associated with hypogonadism and morbid obesity. Nature genetics 1998; 18(3): 213-
215. 
©    2014 Macmillan Publishers Limited. All rights reserved.
18 
 
 
12. Clément K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D et al. A mutation in 
the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 
392(6674): 398-401. 
 
13. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G et al. Dominant and 
recessive inheritance of morbid obesity associated with melanocortin 4 receptor 
deficiency. The Journal of clinical investigation 2000; 106(2): 271-279. 
 
14. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-
4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. The 
Journal of clinical investigation 2000; 106(2): 253-262. 
 
15. Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human 
MC4R is associated with a dominant form of obesity. Nature genetics 1998; 20(2): 
113-114. 
 
16. Yeo GSH, Connie Hung C-C, Rochford J, Keogh J, Gray J, Sivaramakrishnan S et al. 
A de novo mutation affecting human TrkB associated with severe obesity and 
developmental delay. Nature neuroscience 2004; 7(11): 1187-1189. 
 
17. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT et 
al. Obesity and impaired prohormone processing associated with mutations in the 
human prohormone convertase 1 gene. Nature genetics 1997; 16(3): 303-306. 
 
18. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset 
obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations 
in humans. Nature genetics 1998; 19(2): 155-157. 
 
19. Doche ME, Bochukova EG, Su H-W, Pearce LR, Keogh JM, Henning E et al. Human 
SH2B1 mutations are associated with maladaptive behaviors and obesity. The Journal 
of clinical investigation 2012; 122(12): 4732-4736. 
 
20. Bonnefond A, Raimondo A, Stutzmann F, Ghoussaini M, Ramachandrappa S, Bersten 
DC et al. Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-
like features. The Journal of clinical investigation 2013; 123(7): 3037-3041. 
 
21. Ramachandrappa S, Raimondo A, Cali AMG, Keogh JM, Henning E, Saeed S et al. 
Rare variants in single-minded 1 (SIM1) are associated with severe obesity. The 
Journal of clinical investigation 2013; 123(7): 3042-3050. 
 
22. Benzinou M, Creemers JWM, Choquet H, Lobbens S, Dina C, Durand E et al. 
Common nonsynonymous variants in PCSK1 confer risk of obesity. Nature genetics 
2008; 40(8): 943-945. 
©    2014 Macmillan Publishers Limited. All rights reserved.
19 
 
 
23. Creemers JWM, Choquet H, Stijnen P, Vatin V, Pigeyre M, Beckers S et al. 
Heterozygous mutations causing partial prohormone convertase 1 deficiency 
contribute to human obesity. Diabetes 2012; 61(2): 383-390. 
 
24. Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J et al. Prevalence of 
melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance 
in multigenerational pedigrees. Diabetes 2008; 57(9): 2511-2518. 
 
25. Liu X, Jian X, Boerwinkle E. dbNSFP: a lightweight database of human 
nonsynonymous SNPs and their functional predictions. Human mutation 2011; 32(8): 
894-899. 
 
26. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A 
method and server for predicting damaging missense mutations. Nature methods 2010; 
7(4): 248-249. 
 
27. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. 
Nucleic acids research 2003; 31(13): 3812-3814. 
 
28. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates 
disease-causing potential of sequence alterations. Nature methods 2010; 7(8): 575-
576. 
 
29. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. 
Genome research 2009; 19(9): 1553-1561. 
 
30. Farooqi IS, Volders K, Stanhope R, Heuschkel R, White A, Lank E et al. Hyperphagia 
and early-onset obesity due to a novel homozygous missense mutation in prohormone 
convertase 1/3. The Journal of clinical endocrinology and metabolism 2007; 92(9): 
3369-3373. 
 
31. Fugere M, Limperis PC, Beaulieu-Audy V, Gagnon F, Lavigne P, Klarskov K et al. 
Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) 
prodomains. The Journal of biological chemistry 2002; 277(10): 7648-56. 
 
32. Dubern B, Lubrano-Berthelier C, Mencarelli M, Ersoy B, Frelut M-L, Bouglé D et al. 
Mutational analysis of the pro-opiomelanocortin gene in French obese children led to 
the identification of a novel deleterious heterozygous mutation located in the alpha-
melanocyte stimulating hormone domain. Pediatric research 2008; 63(2): 211-216. 
 
33. Hinney A, Becker I, Heibült O, Nottebom K, Schmidt A, Ziegler A et al. Systematic 
mutation screening of the pro-opiomelanocortin gene: identification of several genetic 
variants including three different insertions, one nonsense and two missense point 
©    2014 Macmillan Publishers Limited. All rights reserved.
20 
 
mutations in probands of different weight extremes. The Journal of clinical 
endocrinology and metabolism 1998; 83(10): 3737-3741. 
 
34. Stutzmann F, Vatin V, Cauchi S, Morandi A, Jouret B, Landt O et al. Non-
synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the 
two facets of a Janus obesity gene. Human molecular genetics 2007; 16(15): 1837-
1844. 
 
35. Seidah NG. The proprotein convertases, 20 years later. Methods in molecular biology 
(Clifton, N.J.) 2011; 768: 23-57. 
 
36. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D et al. 
Genome-wide association identifies nine common variants associated with fasting 
proinsulin levels and provides new insights into the pathophysiology of type 2 
diabetes. Diabetes 2011; 60(10): 2624-2634. 
 
37. Frank GR, Fox J, Candela N, Jovanovic Z, Bochukova E, Levine J et al. Severe 
obesity and diabetes insipidus in a patient with PCSK1 deficiency. Molecular genetics 
and metabolism 2013; 110(1-2): 191-194. 
 
38. Jackson RS, Creemers JWM, Farooqi IS, Raffin-Sanson M-L, Varro A, Dockray GJ et 
al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human 
proprotein convertase 1 deficiency. The Journal of clinical investigation 2003; 
112(10): 1550-1560. 
 
39. Martín MG, Lindberg I, Solorzano-Vargas RS, Wang J, Avitzur Y, Bandsma R et al. 
Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and 
other endocrinopathies in a pediatric cohort. Gastroenterology 2013; 145(1): 138-148. 
 
40. Goodman LJ, Gorman CM. Autoproteolytic activation of the mouse prohormone 
convertase mPC1. Biochemical and biophysical research communications 1994; 
201(2): 795-804. 
 
41. Rabah N, Gauthier D, Wilkes BC, Gauthier DJ, Lazure C. Single amino acid 
substitution in the PC1/3 propeptide can induce significant modifications of its 
inhibitory profile toward its cognate enzyme. The Journal of biological chemistry 
2006; 281(11): 7556-67. 
 
42. Basak A, Koch P, Dupelle M, Fricker LD, Devi LA, Chretien M et al. Inhibitory 
specificity and potency of proSAAS-derived peptides toward proprotein convertase 1. 
The Journal of biological chemistry 2001; 276(35): 32720-8. 
 
©    2014 Macmillan Publishers Limited. All rights reserved.
21 
 
43. Basak A, Lazure C. Synthetic peptides derived from the prosegments of proprotein 
convertase 1/3 and furin are potent inhibitors of both enzymes. The Biochemical 
journal 2003; 373(Pt 1): 231-9. 
 
44. He W, Li X, Xu S, Ai J, Gong Y, Gregg JL et al. Aberrant methylation and loss of 
CADM2 tumor suppressor expression is associated with human renal cell carcinoma 
tumor progression. Biochemical and biophysical research communications 2013; 
435(4): 526-532. 
 
45. Kehlen A, Haegele M, Menge K, Gans K, Immel U-D, Hoang-Vu C et al. Role of 
glutaminyl cyclases in thyroid carcinomas. Endocrine-related cancer 2013; 20(1): 79-
90. 
 
46. Park WD, O'Brien JF, Lundquist PA, Kraft DL, Vockley CW, Karnes PS et al. 
Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with 
biochemical phenotype and importance of PTC1-like domains in NPC1. Human 
mutation 2003; 22(4): 313-325. 
 
 
 
 
  
©    2014 Macmillan Publishers Limited. All rights reserved.
22 
 
Table 1. Characteristics of the 13 French families 
Numbers in square brackets shows the number of sequenced DNA samples  
 
Table 2. List of the targeted genes and sequence quality 
 
Table 3. List of rare variants identified in the targeted genes (with a MAF below 1%) 
D, deleterious; PD, probably deleterious; PH, probably harmless; NA, not available; SNP, 
single nucleotide polymorphism 
*MAF according to the public database dbSNP137 
**In silico prediction effect of each variant according to dbNSFP (see Methods)  
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Figure 1. Pedigree of Family #11 showing obesity status of each member, as well as 
genetic status, birth date, age at examination and BMI 
NM denotes the presence of the heterozygous PCSK1 p.Arg80* mutation and NN denotes the 
absence of mutation at the same locus.  
Circles represent female participants and squares male participants. 
Under each participant: genetic status, year of birth, age at examination, BMI (zBMI only for 
children). 
 
Figure 2. Mutant propeptide PC1/3-Arg80* inhibits WT PC1/3 in vitro. 
a) Schematic representation of the propeptide. N-terminal propeptide (PC1/3-Arg80*) has a 
predicted molecular weight of 6.2kDa and the full-length propeptide (PC1/3-Arg110*) has a 
predicted molecular weight of 12.8kDa. 
b) PC1/3 activity was measured using a fluorogenic substrate and conditioned medium from 
HEK293T cells transfected with WT PC1/3 together with conditioned medium of cells 
expressing different constructs as indicated above the figure. Control samples contained only 
medium from cells transfected with empty vector (EV). Activity was normalized to WT 
PC1/3 activity. Error bars represent mean ±SEM, n=5, *P<0.05, **P<0.01.  
c) Co-immunoprecipitation of the mutant propeptide PC1/3-p.Arg80* with WT PC1/3 
enzyme. To specifically label the mutant propeptide, a methionine was introduced at position 
58 (p.Leu58Met).  
d) Western blot of lysate and methanol precipitated medium from HEK293T cells expressing 
WT with or without co-expression of propeptide constructs. A representative image is shown 
(n=4).  
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Table 1. Characteristics of the 13 French families 
Family 
Number of 
generations  
Number of 
relatives 
(Male:Female) 
Number of relatives presenting with: 
Normal 
weight 
Overweight 
Obesity 
Class I 
Obesity 
Class II 
Obesity 
Class III 
1 4 
22 [18]  
(9 [5]:13 [13]) 
8 [8] 5 [5] 1 [1] 2 [0] 6 [4] 
2 4 
18 [14] 
(8 [4]:10 [10]) 
4 [2] 5 [5] 3 [2] 3 [3] 3 [2] 
3 3 
14 [9] 
(6 [4]:8 [5]) 
6 [5] 4 [3] 2 [0] 2 [1] 0 [0] 
4 3 
15 [13] 
(5 [4]:10 [9]) 
7 [7] 3 [1] 4 [4] 0 [0] 1 [1] 
5 3 
15 [12]  
(7 [7]:8 [5]) 
6 [5] 1 [1] 6 [4] 2 [2] 0 [0] 
6 3 
14 [12] 
(5 [4]:9 [8]) 
6 [4] 2 [2] 3 [3] 3 [3] 0 [0] 
7 3 
15 [15] 
(5 [5]:10 [10]) 
8 [8] 2 [2] 2 [2] 2 [2] 1 [1] 
8 3 
20 [17] 
(6 [5]:14 [12]) 
9 [6] 4 [4] 3 [3] 1 [1] 3 [3] 
9 4 
18 [18]  
(8 [8]:10 [10]) 
1 [1] 7 [7] 6 [6] 3 [3] 1 [1] 
10 4 
29 [28] 
(12 [12]:17 [16]) 
9 [9] 10 [10] 4 [4] 0 [0] 6 [5] 
11 3 
10 [10] 
(4 [4]:6 [6]) 
4 [4] 2 [2] 3 [3] 0 [0] 1 [1] 
12 3 
13 [11] 
(6 [4]:7 [7]) 
3 [3] 4 [4] 4 [2] 2 [2] 0 [0] 
13 3 
24 [24] 
(9 [9]:15 [15]) 
13 [13] 8 [8] 2 [2] 1 [1] 0 [0] 
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Table 2. List of the targeted genes and sequence quality 
Gene Transcript ID Gene location 
Monogenic 
obesity 
Common 
obesity 
Median depth of coverage  
[lower quartile - upper quartile] 
BDNF NM_001143805.1 11p13 × × 291 [171 - 411]  
CADM2 NM_001167674.1 3p12.1 
 
× 218 [77 - 352] 
ETV5 NM_004454.2 3q28 
 
× 205 [124 - 311] 
FAIM2 NM_012306.2 12q13 
 
× 87 [45 - 136] 
FTO NM_001080432.2 16q12.2 
 
× 241 [127 - 347] 
GNPDA2 NM_138335.1 4p12 
 
× 270 [189 - 347] 
GPRC5B NM_016235.1 16p12 
 
× 228 [99 - 364] 
KCTD15 NM_001129994.1 19q13.11 
 
× 130 [64 - 240] 
LEP NM_000230.2 7q31.3 × 
 
201 [78 - 293] 
LEPR NM_002303.5 1p31 × 
 
343 [222 - 445] 
LRP1B NM_018557.2 2q21.2 
 
× 281 [192 - 377] 
MAF NM_005360.4 16q22-q23 
 
× 234 [74 - 379] 
MAP2K5 NM_145160.2 15q23 
 
× 116 [66 - 241] 
MC4R NM_005912.2 18q22 × × 341 [260 - 419] 
MTCH2 NM_014342.3 11p11.2 
 
× 243 [143 - 359] 
MTIF3 NM_152912.4 13q12.2 
 
× 209 [56 - 339] 
NEGR1 NM_173808.2 1p31.1 
 
× 339 [221 - 428] 
NPC1 NM_000271.4 18q11.2 
 
× 221 [128 - 334] 
NRXN3 NM_004796.5 14q31 
 
× 287 [184 - 398] 
NTRK2 NM_006180.3 9q22.1 × 
 
306 [166 - 421] 
NUDT3 NM_006703.3 6p21.2 
 
× 243 [121 - 357] 
PCSK1 NM_000439.4 5q15-q21 × 
 
280 [161 - 393] 
POMC NM_000939.2 2p23.3 × × 42 [16 - 101] 
PRKD1 NM_002742.2 14q11 
 
× 259 [155 - 374] 
PTBP2 NM_021190.2 1p21.3 
 
× 326 [206 - 422] 
QPCTL NM_017659.3 19q13.32 
 
× 69 [41 - 115] 
SEC16B NM_033127.2 1q25.2 
 
× 188 [99 - 313] 
SH2B1 NM_001145795.1 16p11.2 × × 63 [35 - 105] 
SIM1 NM_005068.2 6q16.3 × 
 
318 [141 - 451] 
SLC39A8 NM_001135146.1 4q22-q24 
 
× 232 [67 - 370] 
TFAP2B NM_003221.3 6p12 
 
× 225 [108 - 352] 
TMEM18 NM_152834.2 2p25.3 
 
× 157 [78 - 278] 
TNKS NM_003747.2 8p23.1 
 
× 272 [167 - 403] 
TNNI3K NM_015978.2 1p31.1 
 
× 264 [140 - 402] 
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Table 3. List of rare variants identified in the targeted genes (with a MAF below 1%) 
Gene Variant 
Known  
SNP 
MAF* 
Heterozygous carriers Number of 
affected 
families 
Predicted 
severity** 
Ref 
Obese 
Over-
weight 
Normal 
weight 
CADM2 
c.248G>A / 
p.Arg81His 
NA NA 2 0 0 1 PD NA 
FAIM2 
c.287A>G / 
p.Gln96Arg 
rs149184489 NA 2 1 1 2 PD NA 
FAIM2 
c.827T>A / 
p.Leu276Gln 
NA NA 2 2 0 1 PD NA 
FTO 
c.767G>A / 
p.Ser256Asn 
rs144743617 0.001 0 0 2 1 PD NA 
FTO 
c.1418G>A / 
p.Arg473Gln 
NA NA 2 1 1 1 PD NA 
LEPR 
c.611A>G / 
p.Lys204Arg 
rs146442768 NA 1 1 0 1 PH NA 
LRP1B 
c.1379G>A / 
p.Arg460Gln 
NA NA 0 0 1 1 PD NA 
LRP1B 
c.4856G>T / 
p.Arg1619Leu 
NA NA 1 4 0 1 PD NA 
LRP1B 
c.7366G>A / 
p.Val2456Ile 
rs150174082 0.001 0 0 2 1 PD NA 
LRP1B 
c.7420G>A / 
p.Gly2474Ser 
rs146867394 0.005 4 3 2 4 PH NA 
LRP1B 
c.9309G>C / 
p.Trp3103Cys 
NA NA 1 0 1 1 PD NA 
LRP1B 
c.9532G>A / 
p.Ala3178Thr 
rs72899872 0.007 2 1 2 1 PD NA 
LRP1B 
c.12047C>T / 
p.Pro4016Leu 
rs150957163 0.005 2 2 2 2 PD NA 
LRP1B 
c.12161A>C / 
p.Glu4054Ala 
rs79879036 0.003 3 0 1 1 PD NA 
MAF 
c.21G>T / 
p.Met7Ile 
NA NA 0 1 0 1 PD NA 
MC4R 
c.512G>T / 
p.Ser171Ile 
NA NA 0 0 1 1 PD NA 
MC4R 
c.751A>C / 
p.Ile251Leu 
rs52820871 0.004 1 1 2 1 PD 
14
 
MTCH2 
c.357C>G / 
p.His119Gln 
rs75020795 0.001 0 1 0 1 PD NA 
MTCH2 
c.899A>G / 
p.Lys300Arg 
rs73465610 NA 1 2 1 3 PH NA 
MTIF3 
c.413A>G / 
p.Gln138Arg 
rs140262959 0.007 2 1 3 3 D NA 
NEGR1 
c.94C>G / 
p.Leu32Val 
rs142674139 0.003 3 1 1 1 PH NA 
NPC1 
c.665A>G / 
p.Asn222Ser 
rs55680026 0.001 0 0 1 1 PD 
46
 
NPC1 
c.2429T>G / 
p.Val810Gly 
NA NA 6 4 2 7 D NA 
NPC1 
c.2509A>G / 
p.Ile837Val 
NA NA 0 0 2 1 D NA 
NRXN3 
c.924G>C / 
p.Arg308Ser 
rs138594346 NA 0 0 3 1 PD NA 
NRXN3 
c.1219C>T / 
p.Arg407Trp 
rs144412380 NA 0 0 1 1 PD NA 
NRXN3 
c.2311C>A / 
p.Leu771Ile 
NA NA 1 1 2 1 PD NA 
PCSK1 
c.238C>T / 
p.Arg80* 
NA NA 3 0 0 1 PD NA 
PCSK1 
c.539A>G / 
p.Asn180Ser 
NA NA 0 0 2 1 PD 
23
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POMC 
c.430T>C / 
p.Phe144Leu 
rs201408477 0.001 0 1 2 1 PD 
32
 
POMC 
c.641A>G / 
p.Glu214Gly 
rs80326661 0.003 1 0 2 1 PD 
33
 
PRKD1 
c.20T>C / 
p.Leu7Pro 
NA NA 2 0 1 2 PD NA 
PTBP2 
c.95T>G / 
p.Met32Arg 
NA NA 0 0 2 1 PD NA 
PTBP2 
c.1010A>G / 
p.Asn337Ser 
NA NA 0 0 1 1 PD NA 
QPCTL 
c.293T>C / 
p.Leu98Pro 
NA NA 1 0 0 1 D NA 
QPCTL 
c.554C>T / 
p.Thr185Met 
NA NA 0 0 2 1 PD NA 
SH2B1 
c.1156C>A / 
p.Arg386Ser 
NA NA 2 2 2 1 PH NA 
SH2B1 
c.1636A>G / 
p.Thr546Ala 
NA NA 0 0 3 1 D NA 
SH2B1 
c.1988C>T / 
p.Ala663Val 
rs190981290 0.003 0 0 1 1 PD NA 
SIM1 
c.206G>C / 
p.Arg69Pro 
NA NA 1 1 0 1 PD NA 
SLC39A8 
c.745C>G / 
p.Pro249Ala 
rs147912552 0.002 0 1 0 1 PH NA 
TNKS 
c.58C>T / 
p.Pro20Ser 
NA NA 0 1 0 1 PH NA 
TNKS 
c.145A>G / 
p.Thr49Ala 
rs201993870 NA 5 0 2 2 PD NA 
TNKS 
c.410C>A / 
p.Ser137Tyr 
NA NA 0 1 0 1 PD NA 
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